ATE142505T1 - Antikörper, spezifisch gegen elam-1 sowie deren verwendung - Google Patents

Antikörper, spezifisch gegen elam-1 sowie deren verwendung

Info

Publication number
ATE142505T1
ATE142505T1 AT89912817T AT89912817T ATE142505T1 AT E142505 T1 ATE142505 T1 AT E142505T1 AT 89912817 T AT89912817 T AT 89912817T AT 89912817 T AT89912817 T AT 89912817T AT E142505 T1 ATE142505 T1 AT E142505T1
Authority
AT
Austria
Prior art keywords
elam
antibodies specific
expression
detecting
endothelialleukocyte
Prior art date
Application number
AT89912817T
Other languages
English (en)
Inventor
Michael P Bevilacqua
Michael A Gimbrone
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23033111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE142505(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of ATE142505T1 publication Critical patent/ATE142505T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Character Discrimination (AREA)
AT89912817T 1988-11-14 1989-11-14 Antikörper, spezifisch gegen elam-1 sowie deren verwendung ATE142505T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27086088A 1988-11-14 1988-11-14

Publications (1)

Publication Number Publication Date
ATE142505T1 true ATE142505T1 (de) 1996-09-15

Family

ID=23033111

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89912817T ATE142505T1 (de) 1988-11-14 1989-11-14 Antikörper, spezifisch gegen elam-1 sowie deren verwendung

Country Status (8)

Country Link
US (1) US5403713A (de)
EP (1) EP0534944B1 (de)
JP (1) JPH04501565A (de)
AT (1) ATE142505T1 (de)
AU (1) AU636589B2 (de)
CA (1) CA2002860A1 (de)
DE (1) DE68927188T2 (de)
WO (1) WO1990005539A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632991A (en) * 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
EP0585963A1 (de) * 1989-05-23 1994-03-09 Otsuka Pharmaceutical Co., Ltd. Monoklonale Antikörper gegen CMP-170 Antigen auf aktivierten endothelialen Zellen
WO1992008489A1 (en) * 1990-11-08 1992-05-29 Biogen, Inc. Treatment for inflammatory bowel disease
CA2097617A1 (en) * 1990-11-23 1992-05-23 Brian Seed Inhibition of cell adhesion protein-carbohydrate interactions
AU1269092A (en) * 1991-01-24 1992-08-27 Cytel Corporation Monoclonal antibodies to elam-1 and their uses
AU667813B2 (en) * 1991-05-03 1996-04-18 Rockefeller University, The Amino-acid sequence homologies between selectins and B pertussis toxin-peptides derived therefrom antibodies thereto pharmaceutical compositions
US5629162A (en) * 1991-06-11 1997-05-13 The Center For Blood Research Method of identifying agents which modulate ICAM-3 binding to LFA-1
ATE173503T1 (de) * 1991-07-31 1998-12-15 Boehringer Ingelheim Pharma Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma
GB9120768D0 (en) * 1991-09-30 1991-11-13 British Bio Technology Diagnostic and prognastic materials and methods
HUT69725A (en) * 1991-10-01 1995-09-28 Gen Hospital Corp Process for producing compositions for preventing allograft rejection
US5811517A (en) * 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
US5989843A (en) * 1992-01-27 1999-11-23 Icos Corporation Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein
US5525487A (en) * 1992-01-27 1996-06-11 Icos Corporation DNA encoding I-CAM related protein
US6153395A (en) * 1992-01-27 2000-11-28 Icos Corporation ICAM-related protein
US6818743B1 (en) 1992-01-27 2004-11-16 Icos Corporation I-CAM related protein
US6100383A (en) * 1992-01-27 2000-08-08 Icos Corporation Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
WO1993014776A1 (en) * 1992-01-27 1993-08-05 Icos Corporation Icam-related protein
US5532127A (en) * 1992-01-27 1996-07-02 Icos Corporation Assay for 1-CAM related protein expression
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
PT627940E (pt) * 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
ATE161730T1 (de) * 1993-02-09 1998-01-15 Biogen Inc Antikörper zur behandlung von insulinabhängigen diabetes
WO1995018379A1 (en) * 1993-12-27 1995-07-06 The Nisshin Oil Mills, Ltd. Method of assaying complex formed between secretin and ligand thereof and use of said complex
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
IL129767A0 (en) 1996-12-12 2000-02-29 Prolume Ltd Apparatus and method for detecting and identifying infectious agents
WO1998057176A1 (en) * 1997-06-10 1998-12-17 Merck & Co., Inc. Protein elongation factor 2 as a target for antifungal and antiparasitic agents
US6096511A (en) * 1997-06-10 2000-08-01 Merck & Co., Inc. Protein elongation factor 2 as a target for antifungal and antiparasitic agents
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
EP1068224B1 (de) 1998-03-31 2005-05-11 Bristol-Myers Squibb Pharma Company Pharmazeutika zur bildgebung der angiogenischen krankheiten
US6524553B2 (en) * 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US20020160441A1 (en) * 1998-06-02 2002-10-31 Merck & Co., Inc. Protein elongation factor 2 as a target for antifungal and antiparasitic agents
CA2349333A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
EP1140204A2 (de) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronektin-rezeptor antagonist arzeimittheln
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2003028840A2 (en) * 2001-09-27 2003-04-10 Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
BR112022014417A2 (pt) 2020-01-24 2022-09-13 Pfizer Anticorpos anti-e-selectina, composições e métodos de uso

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468464A (en) * 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
US4727028A (en) * 1981-06-22 1988-02-23 Eli Lilly And Company Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US4797277A (en) * 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1

Also Published As

Publication number Publication date
US5403713A (en) 1995-04-04
EP0534944A1 (de) 1993-04-07
JPH04501565A (ja) 1992-03-19
WO1990005539A1 (en) 1990-05-31
DE68927188D1 (de) 1996-10-17
EP0534944A4 (de) 1991-09-23
DE68927188T2 (de) 1997-04-24
AU636589B2 (en) 1993-05-06
CA2002860A1 (en) 1990-05-14
EP0534944B1 (de) 1996-09-11
AU4621789A (en) 1990-06-12

Similar Documents

Publication Publication Date Title
ATE142505T1 (de) Antikörper, spezifisch gegen elam-1 sowie deren verwendung
DK3390A (da) Monoklonalt antistof, som er specifikt for adhaesionsfunktionsdomaenet af et fagocytcelleoverfladeprotein
ES8306714A1 (es) "procedimiento para la obtencion de un compuesto polipeptidico tiolado".
ES1030898U (es) Equipo de ensayo y lectura aplicable especialmente a la prueba de muestras de fluidos corporales.
ATE78697T1 (de) Kombination von angiotensin- converting-enzymehemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln.
DK0669979T3 (da) C-C CKR-1, kemokinreceptor
FI873068A7 (fi) Ilmentämiskasetti hirudiinivariantin tuottamiseksi hiivassa, sitä sisältävä plasmidi, sillä transformoitu hiivasolu ja menetelmä hirudiinivariantin valmistamiseksi hiivasolun avulla
ATE67313T1 (de) Nachweis von menschlichem cytomegalovirusspezifischem igm.
IT1187026B (it) Procedimento per la realizzazione di fogli da un nastro di supproto in materia termoplastica e da uno strato adesivo in elastomerto non reticolabile,come pure dispositivo per l'attuazione del procedimento
IT8548600A0 (it) Pellicole sottili di polietilene ad alto peso molecolare,e procedimento per la loro preparazione
FR2588421B1 (fr) Substrat d'electrode pourvu d'une tubulure, pour une pile a combustible et procede pour le produire
FI953093L (fi) Menetelmiä, joilla voidaan havaita ja hoitaa yksilöitä, joilla on epänormaaleja soluja, jotka ekspressoivat HLA-A2/tyrosinaasi-peptidiantigeenejä
ATA28695A (de) Beiderseits beschichtete aluminiumfolie mit verbesserter tiefziehfähigkeit sowie packung hergestellt unter verwendung dieser aluminiumfolie
AU5944286A (en) Histamine derivatives, immunogen conjugates and antibodies raised thereto
NO962943D0 (no) Peptider og fremgangsmåte mot psoriasis
ATE216709T1 (de) Monoklonäler antikörper gegen die r2-untereinheit von ribonukleotid-reduktase
EP0395669A4 (en) Mouse monoclonal antibodies raised to the t-cell line hsb-2 and t-cell chronic lymphocytic leukemia (t-cll) cells react with normal human t and b lymphocytes and monocytes
BG92796A (bg) Метод за откриване на антитела в кръвта,мембранна лента и мембранна батерия за провеждана на метода
AU538833B2 (en) Method of diagnosing arterosclerosis
ATE130099T1 (de) Verfahren zum nachweis von antikörpern gegen streptokinase.
ES8802545A1 (es) Un metodo para determinar prolil 4-hidroxilasa humana por inmunoensayo enzimatico o radioinmunoensayo
JP2000171467A5 (de)
McCartney Development of instrumentation for use with the 10 S 3. 5 KHz acoustic transponders fitted into experimental penetrators.
DE3854740D1 (de) Menschlicher monoklonaler antikörper gegen candida.
Pasargiklian et al. Laboratory evaluation of a radiometric system.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee